Literature DB >> 28365959

Standard versus extended lymphadenectomy in radical surgical treatment for pancreatic head carcinoma.

Igor Ignjatovic1, Srbislav Knezevic, Djordje Knezevic, Vladimir Dugalic, Marjan Micev, Slavko Matic, Slavenko Ostojic, Marko Bogdanovic, Ivana Pavlovic, Vladimir Jurisic.   

Abstract

PURPOSE: The primary aim of this study was to evaluate the benefit of extended lymphadenectomy in pancreaticoduodenectomy (PD) and to estimate its impact on long-term survival in patients with pancreatic head carcinoma. Secondary endpoints included perioperative mortality, postoperative morbidity and predictors of survival in patients undergoing standard versus extended lymphadenectomy for pancreatic head carcinoma.
METHODS: From January 2007 to December 2010, 60 patients with potentially resectable pancreatic head carcinoma were operated using pylorus-preserving pancreatoduodenectomy (PPPD) at the Clinic for Digestive Surgery, Clinical Center of Serbia, Belgrade. Intraoperatively patients were randomly stratified into two groups: the first group (N1=30) underwent PPPD with standard lymphadenectomy whilst the second group (N2=30) was operated with PPPD with extended lymphadenectomy. None of the patients received adjuvant treatments.
RESULTS: The number of retrieved lymph nodes, mean operating time and postoperative hospital stay were greater in patients with extended lymphadenectomy . Cox regression analysis showed that stage and lymph node metastasis were independent prognostic factors for survival.
CONCLUSION: Extended lymphadenectomy in PPPD did not improve long-term survival in patients with resectable pancreatic head carcinoma and led to comparable and similar morbidity and mortality rates to those after standard lymphadenectomy.

Entities:  

Mesh:

Year:  2017        PMID: 28365959

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  7 in total

Review 1.  Role of Node Dissection in Pancreatic Tumor Resection.

Authors:  Mary Dillhoff; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2021-01-03       Impact factor: 5.344

2.  Survival in resectable pancreatic ductal adenocarcinoma with para-aortic lymph node dissection: A retrospective study in Vietnamese population.

Authors:  Lan Thi Nguyen; Hung Van Nguyen; Dang Hai Do; Khiem Thanh Nguyen; Anh Tuan Do; Ha Hoang Pham; Chinh Duc Nguyen
Journal:  Ann Med Surg (Lond)       Date:  2021-05-01

3.  A nomogram prediction of overall survival based on lymph node ratio, AJCC 8th staging system, and other factors for primary pancreatic cancer.

Authors:  Rui Zhong; Xin Jiang; Yan Peng; Huan Xu; Yongfeng Yan; Li Liu; Xiaowei Tang
Journal:  PLoS One       Date:  2021-05-05       Impact factor: 3.240

4.  Korean Surgical Practice Guideline for Pancreatic Cancer 2022: A summary of evidence-based surgical approaches

Authors:  Seung Eun Lee; Sung-Sik Han; Chang Moo Kang; Wooil Kwon; Kwang Yeol Paik; Ki Byung Song; Jae Do Yang; Jun Chul Chung; Chi-Young Jeong; Sun-Whe Kim
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2022-02-28

5.  Extended lymph node resection versus standard resection for pancreatic and periampullary adenocarcinoma.

Authors:  Ralph F Staerkle; Raphael Nicolas Vuille-Dit-Bille; Christopher Soll; Rebekka Troller; Jaswinder Samra; Milo A Puhan; Stefan Breitenstein
Journal:  Cochrane Database Syst Rev       Date:  2021-01-20

6.  Comparison of prognostic prediction between nomogram based on lymph node ratio and AJCC 8th staging system for patients with resected pancreatic head carcinoma: a SEER analysis.

Authors:  Ning Pu; Jianang Li; Yaolin Xu; Wanling Lee; Yuan Fang; Xu Han; Guochao Zhao; Lei Zhang; Abulimiti Nuerxiati; Hanlin Yin; Wenchuan Wu; Wenhui Lou
Journal:  Cancer Manag Res       Date:  2018-02-05       Impact factor: 3.989

7.  Survival outcomes of pancreaticoduodenectomy versus extended pancreaticoduodenectomy procedure for pancreatic head carcinoma: a propensity score matching study.

Authors:  Ning Pu; Sucheng Mu; Yuan Fang; Hanlin Yin; Gao Liu; Guochao Zhao; Lei Zhang; Wenchuan Wu; Wenhui Lou
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.